BiotechTube
Character Biosciences

Character Biosciences

San Francisco, United States· Est.
characterbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $109M

Overview

Character Biosciences is a private, clinical-stage biotech company pioneering a data-driven approach to treat complex polygenic diseases. By integrating genomics, longitudinal clinical data, imaging, and AI, the company identifies patient subtypes and genetic drivers of disease progression to develop more precise therapeutics. The company has built a robust pipeline with candidates in Phase 1 for dry AMD and geographic atrophy, secured Series B funding from top-tier investors, and assembled a seasoned leadership team with expertise in drug discovery, data science, and clinical development.

OphthalmologyRetinal DiseasesNeurodegenerative Diseases

Technology Platform

An integrated data platform combining human genomics, longitudinal clinical/imaging data, and AI to identify patient subtypes and genetic drivers of disease progression for precision drug discovery and development.

Funding History

3
Total raised:$109M
PIPE$93M
Series A$12M
Seed$4M

Opportunities

Validating its polygenic risk scores in ongoing Phase 1 trials could create a powerful companion diagnostic strategy, de-risking later development and enabling premium pricing.
The platform is potentially expandable to other polygenic diseases beyond ophthalmology, such as cardiovascular or metabolic disorders, offering long-term pipeline growth.

Risk Factors

The core risk is clinical failure of its lead assets, which would also challenge validation of its precision medicine platform.
The company faces intense competition in the AMD space from large pharma and well-funded biotechs.
As a private company, it remains dependent on future financing rounds in a potentially volatile capital market.

Competitive Landscape

Character Bio competes in the crowded AMD therapeutic space against companies like Apellis, Astellas, Regeneron, and Novartis. Its key differentiation is its genetics-driven platform designed to identify responsive patient subtypes, aiming for higher efficacy in targeted populations compared to broader-acting therapies.

More companies in Small Molecule Drugs →More companies in United States →